Literature DB >> 20616588

Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline.

Namiki Izumi1.   

Abstract

In Japan, more than 70% of hepatocellular carcinomas (HCC) develop from hepatitis C virus infections and 15% are derived from hepatitis B infections. Since most have received close observation with e.g. ultrasound or enhanced computed tomography (CT) scan every 3-6 months before development of HCC, the HCC nodule was detected in the early stage in more than 60% of the patients. An algorithm for the HCC surveillance was shown as a Japanese clinical guideline of a scientific-based research group. At the joint symposium with JSH and the International Liver Cancer Association (ILCA), the algorithm of diagnosis and treatment for HCC was discussed using Answerpad. Several important discussions are described in this article. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20616588     DOI: 10.1159/000315234

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  19 in total

Review 1.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

2.  Limitations of screening for hepatocellular carcinoma.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2014-03-20

3.  Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Authors:  Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 4.  Epidemiology and surveillance of hepatocellular carcinoma.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

5.  Biomarker identification of hepatocellular carcinoma using a methodical literature mining strategy.

Authors:  Nai-Wen Chang; Hong-Jie Dai; Yung-Yu Shih; Chi-Yang Wu; Mira Anne C Dela Rosa; Rofeamor P Obena; Yu-Ju Chen; Wen-Lian Hsu; Yen-Jen Oyang
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

6.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

Review 7.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

Review 8.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

9.  Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

Authors:  Norio Hayashi; Chiharu Seto; Mai Kato; Yuji Komada; Shoichiro Goto
Journal:  J Gastroenterol       Date:  2013-09-05       Impact factor: 7.527

10.  Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.

Authors:  Namiki Izumi; Norio Hayashi; Hiromitsu Kumada; Takeshi Okanoue; Hirohito Tsubouchi; Hiroshi Yatsuhashi; Mai Kato; Rito Ki; Yuji Komada; Chiharu Seto; Shoichiro Goto
Journal:  J Gastroenterol       Date:  2014-03-14       Impact factor: 6.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.